A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

<p>Abstract</p> <p>Background</p> <p>Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incid...

Full description

Bibliographic Details
Main Authors: Wang Eunice S, Lyons Roger M, Larson Richard A, Gandhi Sunil, Liu Delong, Matei Carmen, Scott Bart, Hu Kuolung, Yang Allen S
Format: Article
Language:English
Published: BMC 2012-11-01
Series:Journal of Hematology & Oncology
Subjects:
Romiplostim
Lenalidomide
Thrombocytopenia
Myelodysplastic syndrome
Online Access:http://www.jhoonline.org/content/5/1/71

Internet

http://www.jhoonline.org/content/5/1/71

Similar Items